Tandem Non Operating Income Net Other vs Total Other Income Expense Net Analysis
TNDM Stock | USD 35.24 0.32 0.90% |
Tandem Diabetes financial indicator trend analysis is much more than just breaking down Tandem Diabetes Care prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tandem Diabetes Care is a good investment. Please check the relationship between Tandem Diabetes Non Operating Income Net Other and its Total Other Income Expense Net accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Non Operating Income Net Other vs Total Other Income Expense Net
Non Operating Income Net Other vs Total Other Income Expense Net Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tandem Diabetes Care Non Operating Income Net Other account and Total Other Income Expense Net. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Tandem Diabetes' Non Operating Income Net Other and Total Other Income Expense Net is 0.43. Overlapping area represents the amount of variation of Non Operating Income Net Other that can explain the historical movement of Total Other Income Expense Net in the same time period over historical financial statements of Tandem Diabetes Care, assuming nothing else is changed. The correlation between historical values of Tandem Diabetes' Non Operating Income Net Other and Total Other Income Expense Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Operating Income Net Other of Tandem Diabetes Care are associated (or correlated) with its Total Other Income Expense Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Other Income Expense Net has no effect on the direction of Non Operating Income Net Other i.e., Tandem Diabetes' Non Operating Income Net Other and Total Other Income Expense Net go up and down completely randomly.
Correlation Coefficient | 0.43 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Non Operating Income Net Other
Total Other Income Expense Net
Most indicators from Tandem Diabetes' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tandem Diabetes Care current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. At this time, Tandem Diabetes' Selling General Administrative is very stable compared to the past year. As of the 29th of April 2024, Tax Provision is likely to grow to about 2.5 M, while Enterprise Value Over EBITDA is likely to drop (20.24).
2021 | 2023 | 2024 (projected) | Interest Expense | 4.3M | 7.6M | 5.8M | Depreciation And Amortization | 13.8M | 15.7M | 9.4M |
Tandem Diabetes fundamental ratios Correlations
Click cells to compare fundamentals
Tandem Diabetes Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tandem Diabetes fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 326.1M | 716.4M | 905.1M | 1.1B | 952.7M | 1.0B | |
Other Current Liab | 71.5M | 70.5M | 84.4M | 77.6M | 84.6M | 88.8M | |
Total Current Liabilities | 99.4M | 103.9M | 131.9M | 165.3M | 195.3M | 205.0M | |
Total Stockholder Equity | 195.0M | 366.3M | 433.1M | 439.9M | 313.6M | 160.8M | |
Other Liab | 17.7M | 27.4M | 34.8M | 36.1M | 41.5M | 43.6M | |
Property Plant And Equipment Net | 48.5M | 69.8M | 77.9M | 179.2M | 164.3M | 172.5M | |
Net Debt | (30.8M) | 133.7M | 243.5M | 247.4M | 356.8M | 374.6M | |
Retained Earnings | (624.8M) | (659.2M) | (634.6M) | (729.2M) | (951.8M) | (904.2M) | |
Accounts Payable | 17.7M | 17.8M | 28.0M | 55.7M | 49.6M | 52.1M | |
Cash | 51.2M | 94.6M | 71.2M | 172.5M | 58.9M | 65.4M | |
Non Current Assets Total | 50.0M | 79.2M | 93.6M | 202.8M | 204.7M | 214.9M | |
Non Currrent Assets Other | 708K | 580K | 9.1M | 19.0M | 37.6M | 39.4M | |
Other Assets | 708K | 29.2M | 9.1M | 10.7M | 12.3M | 12.9M | |
Cash And Short Term Investments | 176.5M | 484.9M | 623.8M | 616.9M | 467.9M | 242.0M | |
Net Receivables | 46.6M | 82.2M | 110.7M | 114.7M | 105.6M | 110.8M | |
Common Stock Total Equity | 59K | 14.3M | 64K | 65K | 74.8K | 71.0K | |
Common Stock Shares Outstanding | 58.5M | 61.0M | 64.3M | 64.1M | 65.0M | 68.2M | |
Short Term Investments | 125.3M | 390.3M | 552.6M | 444.4M | 409.0M | 429.5M | |
Liabilities And Stockholders Equity | 326.1M | 716.4M | 905.1M | 1.1B | 952.7M | 1.0B | |
Non Current Liabilities Total | 31.7M | 246.3M | 340.2M | 447.5M | 443.8M | 466.0M | |
Inventory | 49.1M | 63.7M | 68.6M | 111.1M | 157.9M | 165.8M | |
Other Current Assets | 4.0M | 6.4M | 8.4M | 7.2M | 16.6M | 17.4M | |
Other Stockholder Equity | 819.6M | 1.0B | 1.1B | 1.2B | 1.3B | 669.8M | |
Total Liab | 131.1M | 350.1M | 472.0M | 612.8M | 639.0M | 671.0M | |
Property Plant And Equipment Gross | 48.5M | 50.0M | 77.9M | 179.2M | 217.1M | 228.0M | |
Total Current Assets | 276.1M | 637.2M | 811.5M | 850.0M | 748.0M | 785.4M | |
Accumulated Other Comprehensive Income | 122K | 220K | (616K) | (1.8M) | 1.4M | 1.4M | |
Common Stock | 59K | 62K | 64K | 65K | 66K | 41.6K | |
Property Plant Equipment | 32.9M | 50.0M | 50.4M | 68.6M | 78.8M | 82.8M | |
Current Deferred Revenue | 3.9M | 6.1M | 10.2M | 18.8M | 44.0M | 46.2M | |
Intangible Assets | 777K | 8.8M | 6.6M | 4.6M | 2.8M | 3.5M | |
Net Tangible Assets | 195.0M | 366.3M | 433.1M | 439.9M | 505.9M | 531.2M | |
Retained Earnings Total Equity | (624.8M) | (659.2M) | (634.6M) | (729.2M) | (656.3M) | (689.1M) | |
Capital Surpluse | 819.6M | 1.0B | 1.1B | 1.2B | 1.3B | 776.1M |
Currently Active Assets on Macroaxis
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Tandem Stock analysis
When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (3.43) | Revenue Per Share 11.509 | Quarterly Revenue Growth (0.11) | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.